TY  - CONF

T1  - DASL-HiCaP: Darolutamide Augments Standard Therapy for Localised Very High-Risk Cancer of the Prostate (ANZUP1801). A randomised phase 3 double-blind, placebo-controlled trial of adding darolutamide to androgen deprivation therapy and definitive or salvage radiation

JO  - ASIA-PACIFIC JOURNAL OF CLINICAL ONCOLOGY

PY  - 2020/01/01

AU  - Sengupta S

AU  - Niazi T

AU  - Williams S

AU  - Davis ID

AU  - Stockler M

AU  - Martin AJ

AU  - Bracken K

AU  - Roncolato FT

AU  - McJannett M

AU  - Horvath L

AU  - Hughes S et al

ED  - 

VL  - 16

SP  - 204

EP  - 204

Y2  - 2024/12/22

ER  -